BridgeBio had a very successful 2025 with a strong commercial launch of Attruby and successful phase 3 readouts of BBP-418 ...

The cost of Attruby can vary based on several factors, including your insurance coverage. Coupons and drug savings programs can also lower the price you’ll pay for Attruby. As with all medications, ...

- Attruby demonstrated the most rapid benefit seen in any Phase 3 study of ATTR-CM to date: - In as few as 3 months, the time to first event (all-cause mortality (ACM) or cardiovascular-related ...

Transthyretin amyloid cardiomyopathy (ATTR-CM) is a condition that can lead to the heart not pumping well. Attruby (acoramidis) was approved in 2024 by the FDA to treat people with ATTR-CM. It has ...

On a Zoom call last month from California, BridgeBio CEO Neil Kumar needled a colleague about the remote possibility of the New York Yankees rallying to win the World Series as they trailed the Los ...

BridgeBio announced the FDA approval of Attruby (acoramidis) for the treatment of patients with ATTR-CM. The label looks clean and it includes all the relevant clinical data. Attruby's approval also ...

BridgeBio received FDA approval for Attruby (acoramidis), a near complete TTR stabilizer (≥90%), approved to reduce cardiovascular death and cardiovascular-related hospitalization in ATTR-CM patients.

Attruby (acoramidis) is a prescription drug that’s used to treat transthyretin amyloid cardiomyopathy (ATTR-CM). Attruby comes as an oral tablet. Attruby is prescribed for adults to treat ATTR-CM. To ...

BridgeBio reports strong demand for Attruby post-FDA approval and enrollment completion in three Phase 3 trials, with significant financial backing. BridgeBio Pharma, Inc. announced significant ...

Attruby’s (acoramidis) dosage for transthyretin amyloid cardiomyopathy is typically two tablets twice per day. Your dosing schedule may vary based on factors such as your symptoms and other ...

The company reiterated its goal of achieving "30-plus percent market share by volume in the years to come" for Attruby. Kumar stated, "The obvious growth in our portfolio today sits with the expansion ...

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. BridgeBio’s recently ...